MDGL: financial statements from SEC — TradeAlmanac

MDGL

Madrigal Pharmaceuticals, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Revenue	311m	287m	213m	137m	62m	15m
Selling, general and administrative	269m	209m	197m	168m	108m	105m
Operating expenses	404m	401m	260m	217m	178m	177m
Operating income	−93m	−114m	−47m	−79m	−116m	−163m
Interest expense	—	—	—	3m	4m	4m
Net income	−94m	−114m	−42m	−73m	−107m	−152m
Earnings per share	−3.25	−5.08	−1.90	−3.32	−4.92	−7.10
Earnings per share, diluted	−3.25	−5.08	−1.90	−3.32	−4.92	−7.10
Weighted average shares	29m	22m	22m	22m	22m	21m
Weighted average shares, diluted	29m	22m	22m	22m	22m	21m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	227m	199m	296m	186m	184m	100m	238m	500m
Receivables	187m	134m	113m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−167m	−89m
Depreciation and amortisation	386,000	379,000
Share-based compensation	34m	21m
Capital expenditure	4m	0
Investing cash flow	192m	164m
Financing cash flow	2m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)